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A B S T R A C T
Vitamin D deficiency is associated with diabetes, cancer, immunological and cardiovascular diseases as well as
increased mortality. It has, however, been difficult to show a causal relation in randomized, controlled trials.
Mendelian randomization studies provide another option for testing causality, and results indicate relations
between the serum 25-hydroxyvitamin D (25(OH)D) level and some diseases, including mortality. We have from
the Tromsø Study in 2012 published non-significant relations been vitamin D related single nucleotide poly-
morphisms (SNPs) and mortality, but have since then genotyped additional subjects, the observation time is
longer and new SNPs have been included. For the present study genotyping was performed for SNPs in the
NADSYN1, CYP2R1, GC and CYP24A1, VDR, CUBILIN and MEGALIN genes in 11 897 subjects who participated
in the fourth survey of the Tromsø Study in 1994–1995. Serum 25(OH)D levels were measured in 6733 of these
subjects. Genetic scores based on SNPs related to the serum 25(OH)D level (NADSYN1 and CYP2R1 SNPs
(synthesis score) and GC and CYP24A1 SNPs (metabolism score)) and serum 25(OH)D percentile groups were
created. Mortality data was updated till end of March 2017 and survival analysed with Cox regression adjusted
for sex and age. During the observation period 5491 subjects died. The 25(OH)D synthesis (but not the meta-
bolism) genetic score and the serum 25(OH)D percentile groups were (without Bonferroni correction) sig-
nificantly related to mortality in favour of high serum 25(OH)D. None of the SNPs in the VDR or MEGALIN genes
were related to mortality. However, for the rs12766939 in the CUBILIN gene with the major homozygote as
reference, the hazard ratio for mortality for the minor homozygote genotype was 1.17 (1.06–1.29), P < 0.002.
This should be viewed with caution, as rs12766939 was not in Hardy-Weinberg equilibrium. In conclusion, our
study confirms a probable causal but weak relation between serum 25(OH)D level and mortality. The relation
between rs12766939 and mortality needs confirmation in more homogenous cohorts.
1. Introduction
The nuclear vitamin D receptor (VDR) is found in most tissues of the
body, and enzymes necessary for the activation of vitamin D to 25-
hydroxyvitamin D (25(OH)D), and finally to 1,25-dihydroxyvitamin D
(1,25(OH)2D), are located not only in the liver and kidneys, but in
peripheral tissues as well. Vitamin D is essential for calcium absorption
and bone health, but may also have a number of other biological
functions, in particular related to cell proliferation and immunology
[1].
Low serum levels of 25(OH)D, which is used as a marker of the
body´s vitamin D stores, are associated with cardiovascular risk factors
like hypertension, hyperglycaemia and hyperlipidaemia, as well as
manifest diseases like cancer, type 2 diabetes, cardiovascular and im-
munological diseases [2]. It has, however, been difficult to show a
beneficial effect of vitamin D supplementation in treatment or pre-
vention of these diseases in randomized, controlled trials (RCTs), pos-
sibly because most of those included have not been in need of supple-
mentation as their 25(OH)D status has been more than adequate [3,4].
There are also ethical problems with including vitamin D deficient
subjects for an extended period of time, and one may therefore not get
the final answer regarding vitamin D supplementation from RCTs.
Another approach is the Mendelian randomization (MR) procedure
[5], and there are several single nucleotide polymorphisms (SNPs) re-
lated to enzymes needed for activation, transport and breakdown of
vitamin D, as well as in the VDR. However, the results have not con-
sistently been in favour of vitamin D. Thus, SNPs related to synthesis
and breakdown of 25(OH)D have been associated with type I diabetes
[6], hypertension [7] and multiple sclerosis [8], whereas not to cardi-
ovascular disease [9], fractures [10], or type 2 diabetes [11]. Similarly,
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there have been numerous studies on VDR SNPs, in particular regarding
cancer, but also these have shown conflicting results [12,13].
One explanation could be that the effect of vitamin D is modest (if
present at all), and therefore a large number of subjects are needed to
show an effect on specific diseases. On the other hand, if there is a
broad-ranging effect of vitamin D as indicated by the overwhelmingly
positive effect in observational studies and the wide-spread localization
of the VDR, one would assume that this would add up to an increased
mortality risk in those with vitamin D deficiency that would be more
easy to demonstrate [14].
A relation to mortality has also been found in meta-analyses of vi-
tamin D RCTs [15,16], but none of the included studies were specifi-
cally designed for that purpose. Similarly, in a large MR study using
SNPs associated to the serum 25(OH)D level, genetically low 25(OH)D
was related to mortality [17], but more studies were asked for [18].
There are also a few MR studies on mortality using VDR SNPs, but these
have been too small to draw firm conclusions [19–21].
We have previously reported a lack of significant association be-
tween 25(OH)D related SNPs and mortality in 9528 subjects followed
for up to 15 years in the Tromsø study [22]. Furthermore, 4465 of these
subjects have been included in a Mendelian randomization analysis on
vitamin D and mortality combining three European cohorts [23], and
7145 of the subjects in a meta-analysis on standardized serum 25(OH)D
and mortality including eight European cohorts [24]. Since then we
have genotyped additional subjects, included genotyping of VDR,
MEGALIN and CUBILIN SNPs, and the observation period is now up to
22 years. In view of the uncertainty regarding vitamin D and mortality,




The Tromsø study is a repeated population-based study conducted
in the municipality of Tromsø, Norway, situated at 69 °N (current po-
pulation 76 000). The study was initiated in 1974, and has been per-
formed seven times at regular intervals. The seventh and latest survey
was conducted in 2015-2016. In the fourth survey in 1994–1995, all
individuals aged 25 years or older and living in Tromsø were invited. A
total number of 27 158 persons participated in the first visit, providing
an attendance rate of 77%. All men aged 55–74 years, all women aged
50–74 years and a sample of 5–10% of the remaining age groups be-
tween 25 and 84 years were invited to a second visit with more ex-
tensive clinical examination, and 7965 persons, or 78% of those invited,
attended [25]. The study was conducted by UiT The Arctic University of
Norway in cooperation with the National Health Screening Service. For
this cohort of 27 158 subjects, specific endpoint registers for myocardial
infarction, type 1 diabetes, stroke, hip and radial fractures, and aortic
stenosis have been created. In addition, data from the Cancer Registry
of Norway and the National Causes of Death Registry were available. In
our initial report in 2012, subjects with one or more of these endpoints
plus a randomly selected control group were included, and all together
9528 subjects were genotyped [22]. For the present study, subjects who
met to the second visit of the fourth survey and who were not geno-
typed in 2012 (n=2369), were now included and genotyped for the
same SNPs as the initial cohort. In addition, all subjects were also
genotyped for several new SNPs.
2.2. Measurements
At the survey in 1994–1995, the participants filled in questionnaires
on medical history and lifestyle factors. Blood pressure, height and
weight, serum total cholesterol and triglycerides were measured and
analyzed as previously described [22]. Sera from the second visit were
stored at −70 °C, and after a median storage time of 13 years, thawed
in March 2008 and analyzed for 25(OH)D using an automated clinical
chemistry analyzer (Modular E170, Roche Diagnostics®, Mannheim,
Germany). The assay overestimates the serum 25(OH)D levels in smo-
kers [26], which was corrected for in the statistical analyses.
2.3. Selection of SNPs
Instead of analyzing all SNPs related to the serum 25(OH)D level
separately, we created genetic scores based on our previous finding of
SNPs most strongly associated with serum 25(OH)D levels [22]. A
25(OH)D synthesis genetic score was based on rs12785878 in the
NADSYN1 gene responsible for the availability of 7-dehydrocholesterol
in the skin, and rs10741657 in the CYP2R1 gene involved in the con-
version of vitamin D into 25(OH)D. A 25(OH)D metabolism genetic
score was based on rs2298850 and rs7041 in the vitamin D binding
protein (DBP) gene (GC gene) and rs6013897 in the CYP24A1 gene
involved in the degradation of 25(OH)D. One point was given for the
allele with highest serum 25(OH)D, two points for the heterozygote,
and three for the allele with the lowest serum 25(OH)D level, and the
points added together. Since SNPs in the VDR have been less studied in
relation to mortality, we included the four most commonly analyzed
VDRSNPs (rs7975232 (Apa1), rs1544410 (Bsm1), rs2228570 (Fok1),
and rs731236 (Taq1)). In addition, we also included two VDR SNPs
(rs2239179 and rs7968585) and two CUBILIN SNPs (rs1801222 and
rs12766939) that recently were reported to have an interaction with
the serum 25(OH)D regarding a composite clinical outcome [27]. A
MEGALIN SNP (rs3755166) was included since the transport of the
vitamin D-DBP complex into the renal tubuli cells depends on the en-
docytic cubulin/megalin system [28].
2.4. Genotyping
Genotyping of the SNPs was performed in blood samples collected
in the fourth survey of the Tromsø study in 1994–1995 by KBiosciences
(http://www.lgcgenomics.com/genotyping/) using a competitive al-
lele-specific polymerase chain reaction (KASPar) assay that enables
highly accurate bi-allelic scoring of SNPs, as previously described in
detail [22].
2.5. Statistical analyses
The relations between SNP genotypes, and mortality were evaluated
in Cox regression analyses with age and gender as covariates and with
the major homozygote genotype used as reference. The observation
time was set from 1994 to 1995, and the period of observation was cut
off by March 2017. Information on death was obtained from the Causes
of Death Registry, updated till March 2017. In further analyses, risk
factors for mortality as BMI, systolic blood pressure, serum lipids, and
smoking were included as covariates to examine if relations could be
explained through these risk factors.
Distribution of the continuous variables serum 25(OH)D, blood
pressure, lipids and BMI was evaluated for skewness and curtosis and
visual inspection of histograms and found normal except for serum
triglycerides which was normalized by log transformation before use as
dependent variable. Trends across the genotypes were evaluated with
linear regression with age and gender as covariates.
For the relation between serum 25(OH)D and mortality, adjust-
ments for season and smoking were performed by calculating 25(OH)D
percentiles for each month for smokers and non-smoker separately.
Based on this, the cohort was then divided in the following serum
25(OH)D percentile groups: 0–10 percentile, 11–25 percentile, 26–50
percentile, and> 50 percentile.
The genotype frequencies were examined for compliance with
Hardy-Weinberg equilibrium using chi-squared analysis [29]. Linkage
disequilibrium (LD) between SNPs was evaluated with r2 and Le-
wontin's D′ statistics [30,31].
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The data are shown as mean ± SD. All tests were done two-sided,
and a P-value< 0.05 was considered statically significant. The P-values
are shown without corrections for multiple comparisons.
2.6. Ethics
The study was approved by the Regional Committee for Medical and
Health Research Ethics (REK Nord) (reference 2010/2913-4). Only
participants with valid written consent were included.
3. Results
3.1. Baseline
A total of 11 897 subjects had at least one SNP successfully ana-
lyzed, 5347 (44.9%) men and 6550 (55.1%) women, and were included
in the analyses. Among these, 33.7% were current smokers at baseline.
In 1994–1995 their mean ± SD age was 57.8 ± 13.6 years and BMI
25.9 ± 4.1 kg/m2.
The individual SNP analyses were successful in 98.8–99.5% of the
subjects. The genotypes for all the SNPs were in Hardy-Weinberg
equilibrium except for rs12766939 in the CUBILIN gene (Chi square
8.36, P < 0.01), and rs12785878 in the NADSYN1gene (Chi square
7.97, P < 0.01). The VDR SNPs rs7975232 (Apa1), rs1544410 (Bsm1),
and rs731236 (Taq1) were in LD with each other (r2> 0.4) and also
with rs2239179 and rs7968585 (r2> 0.4). Rs2239179 and rs7968585
were in moderate LD (r2= 0.386). None of the other SNPs (including
rs2228570 (Fok1)) were in LD.
Among the 11 897 subjects, serum 25(OH)D was analyzed in 6733
subjects. The mean differences in serum 25(OH)D between the major
and minor homozygote for rs12785878, rs10741657, rs2298850,
rs7041 and rs6013897 were 2.0, 2.8, 8.3, 6.1, and 2.2 nmol/L, re-
spectively. For the other SNPs tested, there was only a significant dif-
ference of 1.5 nmol/L in serum 25(OH)D for the VDR SNP rs2228570
(Fok1). The mean differences in serum 25(OH)D between highest and
lowest 25(OH)D synthesis and metabolism genetic scores were 3.6 and
9.5 nmoL/L, respectively (Table 1). These score predicted 0.3 and 1.8%,
respectively, of the variation in the serum 25(OH)D levels.
There were no statistically significant differences between the
genotypes regarding age and gender, smoking status, systolic blood
pressure or serum cholesterol. However, for the 25(OH)D synthesis
genetic score, there was a significant association with serum triglycer-
ides with the highest triglyceride levels in those with the highest ge-
netic score (lowest serum 25(OH)D) (linear trend, P= 0.023).
Subjects in the lowest serum 25(OH)D percentile group had higher
BMI, systolic blood pressure and serum triglyceride levels than those in
higher serum 25(OH)D percentiles (linear trend, P < 0.001) (Table 1).
3.2. Cox regression
During the observation period 5491 subjects (2762 men and 2729
women) had died. In the Cox regression analysis, only the CUBILIN SNP
rs12766939, the 25(OH)D synthesis genetic score, and the serum
25(OH)D percentile groups were significantly associated with mortality
(Table 2) and Figs. 1–3. These associations were not significantly af-
fected by inclusion of systolic blood pressure, BMI, smoking status,
serum cholesterol and serum triglycerides in the Cox regression ana-
lysis. When including serum 25(OH)D as a continuous variable (redu-
cing the number of subjects to 6655), the same patterns for CUBILIN
SNP rs12766939 and the 25(OH)D synthesis genetic score and mor-
tality were seen, but the relations were no longer statistically significant
(data not shown). There was no significant interaction between the
CUBILIN SNP rs12766939 (or any of the other SNPs) and the serum
25(OH)D level regarding mortality.
4. Discussion
In the present study we have confirmed the relation between low
serum 25(OH)D and mortality. We have also found a weak relation
between a 25(OH)D synthesis genetic score (based on SNPs in the
NADSYN1 and CYP2R1 genes) and mortality, and possibly also a rela-
tion between one SNP in the CUBILIN gene and mortality. However, no
significant relations between mortality and VDR and MEGALIN SNPs, or
a genetic score based on SNPs involved in transportation and de-
gradation of 25(OH)D, were found.
As for the relation between serum 25(OH)D level and mortality, this
is well established in numerous studies [24,32–34], and was in our
study not affected by adjusting for sex or age, nor for the cardiovascular
risk factor smoking, BMI, systolic blood pressure, or serum lipids. Due
to the high risk of reverse causality a low serum 25(OH)D may be the
result as well as the cause of disease. Ideally, associations should
therefore be confirmed in properly designed RCTs. However, there has
been no RCT performed specifically for vitamin D and mortality. It is
unrealistic that such an RCT will ever be performed, but meta-analyses
of available data have indicated a protective effect by vitamin D sup-
plementation [15,35]. The validity of this conclusion has, however,
been questioned [36].
An approach to eliminate effects of confounders is MR studies, but
so far there is only one large MR study on vitamin D and mortality.
Thus, Afzal et al. included 95 766 subjects from three Danish cohorts,
and during mean observation times of 5 to 19 years, 10 349 subjects
died. SNPs in the DHCR7 (NADSYN1) and CYP2R1 genes were used to
create a 25(OH)D synthesis genetic score similar ours, and a genetically
20 nmol/L lower serum 25(OH)D level gave an odds ratio for mortality
of 1.30 (1.05–1.61) [17]. Even if this study is impressive, it should be
recalled that this group also published a significant association between
25(OH)D SNPs and type 2 diabetes in a cohort of 96 423 subjects with
5037 cases [37], a finding that could not be reproduced in an even
larger study [11].
It was therefore prudent that the editorial following the Afzal et al.
mortality publication asked for confirmatory studies [18], and several
more, but smaller, MR studies have now been published. Thus, Or-
donez-Mena et al. included 8417 subjects of whom 1338 died during
the mean observation time of 11 years, but found no relation to serum
25(OH)D associated SNPs [38]. On the other hand, in the study by
Aspelund et al. [23] who included 10 501 subjects from three European
cohorts (including parts of our present cohort) where 4003 subjects
died during a median observation time of 10.4 years, the relation be-
tween a 25(OH)D genetic score and mortality was comparable to the
one reported by Afzal et al. [17]. However, it did not reach statistical
significance, probably due to lack of power. This is very similar to our
findings, with a ˜ 15% increased mortality risk in those with less fa-
vourable 25(OH)D synthesis genetic scores (associated with lower
serum 25(OH)D) compared to the ones with the most favourable score.
However, this would not reach statistical significance if adjusted for
multiple testing. Furthermore, rs12785878 in the NADSYN1 gene,
which was part of our 25(OH)D synthesis genetic score, was not in
Hardy-Weinberg equilibrium. This can be explained by the high pro-
portion with Sami ancestry in the Tromsø population [39], as this SNP
has a considerable difference in allele frequency between Asian and
Western populations [40]. Our results could therefore be biased, and
the findings by Afzal et al. [17] on mortality and vitamin D are so far
not confirmed with certainty.
In addition to the 25(OH)D synthesis genetic score, we also created
a 25(OH)D metabolism genetic score based on three SNPs in the GC and
CYP24A1 genes related to transportation and degradation of 25(OH)D
[22]. In spite of a larger difference in serum 25(OH)D between the
highest and lowest metabolism genetic scores than between the highest
and lowest synthesis genetic scores, no significant relation to mortality
was found for the 25(OH)D metabolism genetic score. This could in-
dicate that the genes involved in these scores have pleiotropic effects
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Table 1
Baseline characteristics (1994–1995) in relation to genotypes, genetic scores and serum 25(OH)D. The Tromsø Study.









Major homozygote 4077 55.5 33.6 58.0 ± 13.5 25.9 ± 4.1 143 ± 23 6.57 ± 1.33 1.68 ± 1.12 58.7 ± 20.1
Heterozygote 5643 55.0 34.2 57.8 ± 13.6 25.8 ± 4.1 143 ± 23 6.54 ± 1.31 1.63 ± 1.04 59.2 ± 20.3
Minor homozygote 2075 54.7 33.8 57.6 ± 13.6 25.8 ± 4.0 143 ± 23 6.54 ± 1.32 1.67 ± 1.08 59.0 ± 20.1
VDR rs1544410 (Bsm1)
Major homozygote 4011 54.6 33.8 57.6 ± 13.6 25.8 ± 4.0 143 ± 23 6.57 ± 1.32 1.67 ± 1.08 59.2 ± 20.1
Heterozygote 5654 55.1 33.9 57.8 ± 13.5 25.8 ± 4.1 143 ± 24 6.52 ± 1.32 1.64 ± 1.07 58.8 ± 20.2
Minor homozygote 2085 55.4 33.9 58.6 ± 13.6 25.9 ± 4.1 143 ± 23 6.58 ± 1.31 1.69 ± 1.09 59.0 ± 20.4
VDR rs2228570 (Fok1)
Major homozygote 5006 54.7 34.1 57.8 ± 13.5 25.9 ± 4.1 143 ± 23 6.57 ± 1.34 1.67 ± 1.10 58.2 ± 20.2
Heterozygote 5368 55.4 33.8 57.9 ± 13.6 25.9 ± 4.1 143 ± 23 6.53 ± 1.32 1.65 ± 1.05 59.4 ± 20.4
Minor homozygote 1433 54.7 33.5 58.0 ± 13.6 25.6 ± 4.1 141 ± 22 6.54 ± 1.28 1.65 ± 1.11 59.7 ± 19.3†
VDR rs731236 (Taq1)
Major homozygote 4017 54.6 33.6 57.6 ± 13.6 25.8 ± 4.0 143 ± 23 6.57 ± 1.33 1.67 ± 1.08 59.1 ± 20.1
Heterozygote 5692 55.3 33.7 57.8 ± 13.6 25.9 ± 4.1 143 ± 24 6.52 ± 1.32 1.64 ± 1.07 58.7 ± 20.1
Minor homozygote 2096 55.7 34.5 58.6 ± 13.5 25.9 ± 4.1 143 ± 23 6.59 ± 1.30 1.69 ± 1.10 59.2 ± 20.4
VDR rs2239179
Major homozygote 3243 54.3 34.1 57.6 ± 13.6 25.9 ± 4.0 143 ± 23 6.56 ± 1.32 1.67 ± 1.10 59.2 ± 20.3
Heterozygote 5892 55.2 33.5 57.8 ± 13.6 25.8 ± 4.1 143 ± 24 6.54 ± 1.31 1.64 ± 1.05 58.6 ± 20.1
Minor homozygote 2673 55.8 34.2 58.2 ± 13.4 25.9 ± 4.1 144 ± 23 6.57 ± 1.34 1.69 ± 1.10 59.2 ± 20.1
VDR rs7968585
Major homozygote 3620 54.9 34.1 57.9 ± 13.6 25.9 ± 4.1 143 ± 23 6.56 ± 1.32 1.67 ± 1.09 59.1 ± 20.3
Heterozygote 5728 55.4 34.0 57.8 ± 13.5 25.8 ± 4.1 143 ± 23 6.53 ± 1.31 1.64 ± 1.07 59.0 ± 20.1
Minor homozygote 2402 54.4 33.7 57.8 ± 13.7 25.8 ± 4.0 143 ± 23 6.57 ± 1.32 1.68 ± 1.09 59.0 ± 20.1
MEGALIN rs3755166
Major homozygote 4294 57.3 34.0 57.8 ± 13.7 25.8 ± 4.1 143 ± 23 6.53 ± 1.32 1.63 ± 1.04 59.1 ± 20.0
Heterozygote 5572 53.4 34.2 57.5 ± 13.4 25.9 ± 4.1 143 ± 23 6.55 ± 1.32 1.69 ± 1.11 59.2 ± 20.4
Minor homozygote 1787 55.0 32.7 58.0 ± 13.7 25.8 ± 4.0 143 ± 23 6.59 ± 1.33 1.64 ± 1.04 58.0 ± 19.7
CUBILIN rs1801222
Major homozygote 5036 55.3 34.0 58.0 ± 13.5 25.9 ± 4.0 144 ± 24 6.58 ± 1.34 1.68 ± 1.12 58.8 ± 19.8
Heterozygote 5319 54.9 33.9 57.7 ± 13.7 25.8 ± 4.1 143 ± 23 6.54 ± 1.32 1.65 ± 1.05 59.0 ± 20.6
Minor homozygote 1390 54.9 33.8 57.9 ± 13.4 25.8 ± 4.1 142 ± 23 6.49 ± 1.28 1.61 ± 1.00 59.3 ± 19.8
CUBILIN rs12766939
Major homozygote 9431 55.4 33.4 57.9 ± 13.7 25.8 ± 4.1 143 ± 23 6.54 ± 1.31 1.65 ± 1.07 58.6 ± 20.1
Heterozygote 4442 55.2 34.5 57.8 ± 13.3 25.8 ± 4.1 143 ± 23 6.57 ± 1.32 1.66 ± 1.06 59.5 ± 20.3
Minor homozygote 878 53.2 33.1 58.0 ± 14.0 26.0 ± 4.0 144 ± 24 6.59 ± 1.39 1.72 ± 1.21 58.7 ± 19.7
25(OH)D synthesis
genetic score**
Score 2 (high 25(OH)
D)
744 54.6 34.6 57.5 ± 13.7 25.7 ± 4.2 142 ± 24 6.50 ± 1.31 1.58 ± 0.97 61.4 ± 21.1
Score 3 3088 55.5 34.2 57.6 ± 13.5 25.9 ± 4.1 143 ± 23 6.54 ± 1.31 1.64 ± 1.01 60.3 ± 20.4
Score 4 4620 54.2 33.3 58.1 ± 13.5 25.8 ± 4.0 143 ± 23 6.57 ± 1.32 1.68 ± 1.10 58.9 ± 20.2
Score 5 2662 56.2 34.1 57.7 ± 13.8 25.9 ± 4.2 143 ± 23 6.56 ± 1.34 1.66 ± 1.11 57.2 ± 19.9
Score 6 616 56.0 34.7 58.0 ± 13.6 25.8 ± 4.2 142 ± 23 6.56 ± 1.34 1.71 ± 1.16† 57.8 ± 18.7††
25(OH)D metabolism
genetic score***
Score 3 (high 25(OH)
D)
2092 52.8 34.3 57.8 ± 13.4 25.8 ± 4.1 143 ± 23 6.54 ± 1.33 1.69 ± 1.12 62.3 ± 20.4
Score 4 2844 56.2 34.7 57.4 ± 13.8 25.9 ± 4.1 143 ± 23 6.53 ± 1.32 1.65 ± 1.04 61.1 ± 20.6
Score 5 3357 55.4 35.0 57.8 ± 13.5 25.8 ± 4.1 1443 ± 23 6.57 ± 1.33 1.66 ± 1.09 58.7 ± 20.2
Score 6 2054 55.7 31.9 58.4 ± 13.8 25.9 ± 4.1 142 ± 23 6.55 ± 1.30 1.62 ± 1.03 56.3 ± 19.2
Score 7 987 54.5 32.6 58.0 ± 13.6 25.8 ± 4.0 144 ± 24 6.57 ± 1.29 1.72 ± 1.16 53.8 ± 18.3
Score 8 – 9 309 54.0 29.8 58.4 ± 12.3 26.1 ± 3.8 143 ± 23 6.51 ± 1.40 1.69 ± 1.02 52.8 ± 19.4††
Percentile serum
25(OH)D****
0-10 669 68.8 32.0 59.9 ± 11.5 26.9 ± 5.0 146 ± 24 6.64 ± 1.24 1.81 ± 1.09 32.6 ± 9.6
11-25 1022 63.6 32.9 59.9 ± 10.6 26.6 ± 4.6 147 ± 24 6.74 ± 1.35 1.76 ± 1.09 43.6 ± 9.6
26-50 1681 58.9 32.3 59.5 ± 10.2 26.1 ± 4.1 144 ± 23 6.75 ± 1.27 1.74 ± 1.12 52.9 ± 10.5
> 50 3361 59.8††† 32.6 58.2 ± 9.9 25.5 ± 3.6††† 141 ± 22††† 6.72 ± 1.31 1.52 ± 0.91††† 72.0 ± 17.7†††
Numbers, percentages, or mean ± SD.
* N=6734.
** Sum of NADSYN1 rs12785878 and CYP2R1 rs10741657 scores where the allele with the highest 25(OH)D is given a score of 1, the homozygote 2, and the allele
with the lowest 25(OH)D a score of 3.
*** Sum of GC rs2298850 and rs7041 and CYP24A1 rs6013897 scores where the allele with the highest 25(OH)D is given a score of 1, the homozygote 2, and the
allele with the lowest 25(OH)D a score of 3.
**** Month of blood sampling specific, calculated for smokers and non-smokers separately.
† P<0.05; ††P < 0.01; †††P < 0.001.
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[41]. In particular, the GC gene has profound effect not only on the
serum 25(OH)D concentrations, but obviously also on the vitamin D
binding protein, which by itself has a number of potential physiological
effects [42].
For 125(OH)2D, the active form of vitamin D, to have an effect, it
has to connect to its nuclear receptor VDR. Mutations in the VDR could
change the affinity of the receptor for 125(OH)2D, and numerous VDR
SNPs have been described. However, the biological functions of these
SNPs are uncertain, and effects associated with them ascribed to hap-
lotype connections or linkage to truly functional polymorphisms
elsewhere in the VDR [43]. This is the case for the most studied VDR
SNPs Apa1, Bsm1, Taq1, and Fok1 that in particular have been analyzed
in relation to cancer, but with inconsistent results [12]. There are only a
few studies on these VDR SNPs and mortality, and as for cancer the
results are non-conclusive. Thus, de Jongh et al. included 923 subjects
of whom 480 participants deceased during the median follow up time of
10.7 years, but found no significant relations to mortality for the Apa1,
Bsm1, Taq1, and Fok1 SNPs, nor when analyzing their haplotypes [19].
Similarly, Perna et al. found no relation between VDR polymorphisms
and mortality in 1397 colorectal cancer patients [20], whereas Marco
Table 2
Cox regression with adjustment for age and gender for death in relation to genotypes, genetic scores, and serum 25(OH)D percentile groups. The Tromsø
Study.1994–2015.
Gene and genotype N Dead (%) Hazard ratio 95 % confidence interval SignficantP values
VDR rs7975232 (Apa1)
Major homozygote 4077 46.6 Reference
Heterozygote 5643 45.5 0.982 0.926 – 1.042
Minor homozygote 2075 47.0 0.996 0.922 – 1.076
VDR rs1544410 (Bsm1)
Major homozygote 4011 47.2 Reference
Heterozygote 5654 44.8 0.963 0.907 – 1.022
Minor homozygote 2085 48.4 1.018 0.943 – 1.099
VDR rs2228570 (Fok1)
Major homozygote 5006 6.0 Reference
Heterozygote 5368 46.2 0.993 0.938 – 1.051
Minor homozygote 1433 56.6 1.015 0.931 – 1.106
VDR rs731236 (Taq1)
Major homozygote 4017 47.1 Reference
Heterozygote 5692 44.7 0.962 0.907 – 1.022
Minor homozygote 2096 48.4 1.021 0.946 – 1.102
VDR rs2239179
Major homozygote 3243 46.4 Reference
Heterozygote 5892 45.3 1.003 0.942 – 1.069
Minor homozygote 2673 47.5 1.037 0.963 – 1.118
VDR rs7968585
Major homozygote 3620 46.5 Reference
Heterozygote 5728 45.2 0.965 0.907 – 1.026
Minor homozygote 2402 47.7 1.006 0.933 – 1.084
MEGALIN rs3755166
Major homozygote 4294 46.6 Reference
Heterozygote 5572 46.0 1.025 0.966 – 1.086
Minor homozygote 1787 44.8 0.943 0.869 – 1.024
CUBILIN rs1801222
Major homozygote 5036 47.1 Reference
Heterozygote 5319 45.7 0.966 0.912 – 1.022
Minor homozygote 1390 44.3 0.935 0.856 – 1.022
CUBILIN rs12766939
Major homozygote 9431 45.9 Reference
Heterozygote 4442 45.5 1.005 0.949 – 1.063
Minor homozygote 878 50.8 1.172 1.061 – 1.295 0.002
25(OH)D synthesis genetic score*
Score 2 (high 25(OH)D) 744 41.1 Reference
Score 3 3088 46.3 1.167 1.032 – 1.321 0.014
Score 4 4620 47.1 1.159 1.028 – 1.307 0.016
Score 5 2662 45.6 1.137 1.003 – 1.289 0.044
Score 6 616 46.8 1.156 0.984 – 1.358
25(OH)D metabolism genetic score**
Score 3 (high 25(OH)D) 2092 46.4 Reference
Score 4 2844 45.8 0.986 0.908 – 1.072
Score 5 3357 45.6 0.949 0.875 – 1.028
Score 6 2054 47.0 0.951 0.870 – 1.039
Score 7 987 46.9 0.961 0.860 – 1.074
Score 8-9 309 50.8 1.071 0.905 – 1.268
Percentile serum 25(OH)D***
0-10 669 48.0 1.188 1.051 – 1.344 0.006
11-25 1022 46.3 1.050 0.945 – 1.167
26-50 1681 42,8 0.981 0.897 – 1.074
> 50 (high 25(OH)D) 3361 40.0 Reference
* Sum of NADSYN1 rs12785878 and CYP2R1 rs10741657 scores where the allele with the highest 25(OH)D is given a score of 1, the homozygote 2, and the allele
with the lowest 25(OH)D a score of 3.
** Sum of GC rs2298850 and rs7041 and CYP24A1 rs6013897 scores where the where the allele with the highest 25(OH)D is given a score of 1, the homozygote 2,
and the allele with the lowest 25(OH)D a score of 3.
*** Month of blood sampling specific, calculated for smokers and non-smokers separately.
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et al. found a relation between Bsm1 polymorphism and survival in 143
subjects on hemodialysis [21]. To our knowledge our study is therefore
the largest where these SNPs have been analyzed in relation to mor-
tality, but the results were negative.
We also included two other VDR SNPs (rs2239179 and rs7968585)
since they in a study by Levin et al. were found to modify the asso-
ciation between serum 25(OH)D and a composite outcome consisting of
hip fracture, myocardial infarction, cancer and mortality [25]. How-
ever, we could not find an association between these SNPs and mor-
tality, nor did we find an interaction with low serum 25(OH)D levels.
This is in agreement with the studies by Ordonez-Mena et al. [38] and
Vimaleswaran et al. [44]. Even though the concept of interaction be-
tween an altered VDR receptor and vitamin D deficiency is appealing,
this still needs supportive data.
Other elements in the vitamin D metabolism are the endocytic re-
ceptors megalin and cubulin, which are present in the renal tubuli cells
[45] and enable transportation of the DBP-vitamin D complexes and
other filtered proteins into the cells [28]. Cubilin dysfunction may lead
to urinary loss of vitamin D in the urine and cause abnormal metabo-
lism of 25(OH)D [46], and MEGALIN polymorphisms are associated
with adiposity [47]. Furthermore, an interaction between CUBILIN
SNPs and serum 25(OH)D level was also described by Levin et al. [27].
Again, we could not confirm such interactions, but the CUBILIN SNP
rs12766939 was significantly associated with mortality, which to our
knowledge has not been reported before. It should be noted though that
this SNP, similar to rs12785878 in the NADSYN1 gene, was not in
Hardy-Weinberg equilibrium and probably for the same mixed-popu-
lation reason. Our results should therefore be considered as exploratory
and need confirmation in other populations. Furthermore, this SNP was
not associated with lower serum 25(OH)D levels, and the association to
mortality probably more related to altered reabsorption of other pro-
teins or protein-complexes in the renal proximal tubule or the intestine
[48].
Our study has several important limitations. Although there is a
fairly strong heritability of the serum 25(OH)D level, which from twin
studies has been estimated to be between 20 to 85% [49], our genetic
scores can only explain a fraction of this heritability. Recently a SNP in
the CYP2R1 gene was identified with a 3 to 4 fold larger effect size on
the serum 25(OH)D level than the CYP2R1 SNP included by us [8]. This
SNP has a minor allele frequency< 5% and shows a strong relation to
risk of multiple sclerosis [8]. Genotyping for this SNP (and similar SNPs
detected when SNPs with low minor allele frequency related to serum
25(OH)D are sought for) would of course give the MR analysis much
more power. Furthermore, our VDR SNPs are probably non-functional,
and significant clinical effects unlikely unless these SNPs by chance are
coupled to truly functional SNPs. We did not adjust for multiple testing,
which would have made the relation with mortality for the 25(OH)D
synthesis genetic score and the serum 25(OH)D percentile groups non-
significant. Some of our SNPs were not in Hardy Weinberg equilibrium.
The results should therefore be interpreted with caution, and the rela-
tion between the CUBILIN SNP rs12766939 and mortality (which was
highly significant even after Bonferroni correction) should be con-
sidered as exploratory.
Our study also has strengths. It is, to our knowledge, the largest on
VDR, CUBILIN and MEGALIN SNPs and mortality, and the results re-
garding the 25(OH)D synthesis genetic score are in line with similar
studies.
In conclusion, the questions regarding vitamin D and mortality are
still unanswered. Although MR studies also have their limitations [5],
discovery of SNPs more strongly related to serum 25(OH)D levels and
SNPs with direct effects on the function of the VDR, might hopefully
bring us closer to an answer.
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Fig. 1. Cumulative probability of survival according to a 25(OH)D synthesis
genetic score based on SNP rs12785878 in the NADSYN1 gene and SNP
rs10741657 in the CYP2R1 gene, Cox regression with age and sex as covariates.
Low genetic score corresponds to high serum 25(OH)D level.
Fig. 2. Cumulative probability of survival according to rs12766939 genotypes
(in the CUBILIN gene), Cox regression with age and sex as covariates.
Fig. 3. Cumulative probability of survival according to serum 25(OH)D per-
centile score group (month specific), Cox regression with age and sex as cov-
ariates.
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